Challenges in the Diagnosis and Management of Low-Grade Gliomas

World Neurosurg. 2022 Oct:166:313-320. doi: 10.1016/j.wneu.2022.06.074.

Abstract

Low-grade gliomas are clinically challenging entities. Patients with these tumors tend to be relatively young at presentation, and lesions are often incidental findings or are identified because the patient presents with a seizure. Rapidly emerging and evolving molecular classifications of gliomas have influenced treatment paradigms. Importantly, low-grade gliomas can be classified on the basis of IDH mutation status, whereby low-grade astrocytomas harbor the IDH mutation, while oligodendrogliomas are defined by both IDH mutant status and 1p/19q co-deletion. Given the importance of molecular classification for diagnosis, treatment planning, and prognostication, tissue samples are necessary for proper management. Literature supports improved overall survival and outcomes with increased extent of resection for low-grade glioma. Awake craniotomies and resection of insular low-grade gliomas both have been demonstrated as safe and improve outcomes for patients with lesions located in eloquent areas. Given the younger age at diagnosis of these lesions compared with higher-grade gliomas, fertility, fertility preservation, and potential malignant transformation should be discussed with patients of childbearing age.

Keywords: Brain tumor; Challenges; Classification; Low-grade glioma; Surgical management; Treatment.

MeSH terms

  • Brain Neoplasms* / diagnosis
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / surgery
  • Chromosomes, Human, Pair 1
  • Glioma* / diagnosis
  • Glioma* / genetics
  • Glioma* / surgery
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation / genetics
  • Oligodendroglioma*

Substances

  • Isocitrate Dehydrogenase